RecruitingObstructive Sleep Apnea

Magnetic Apnea Prevention(MAGNAP) Device to Treat Obstructive Sleep Apnea:First-In-Human Study of Feasibility and Safety

Eligible age

21–70 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The purpose of this study is to determine the safety and feasibility of the Magnap magnetic device in the treatment of obstructive sleep apnea (OSA).

Sponsor: Michael Harrison

✓ Patient is between 21 and ≤70 years of age
✓ Subject has moderate to severe obstructive sleep apnea (defined as apnea-hypopnea index of 15-50 events/hour on baseline/screening polysomnogram)
✓ Subject is intolerant of positive airway pressure therapy (defined as \<2 hours of sleep time with use per night for at least 5 nights per week as measured objectively by evaluation of continuous positive airway pressure (CPAP) machine memory chip and interpreted by the study sleep medicine specialist)
✓ Subject signs and dates a written informed consent form and indicates understanding of the study procedures and risks

✕ Any evidence that apnea is not caused by base of tongue (i.e., central apnea, neurologic disorder, retropalatal collapse, nasal obstruction)
✕ Any condition likely requiring MRI or has a metal implant
✕ Any factor that, in the surgeon's judgment, would pose a risk to surgery or placement of a long-term implanted device
✕ Any factor that, in the surgeon's judgment, would make the subject unlikely to respond to Magnap treatment
✕ Congenital anomalies of the larynx, pharynx, or trachea or any other anatomical abnormality of the head, neck, or chest that would be a contraindication to placement of the Magnap device and usage of the external device
✕ There are no exclusion criteria based on gender, race or ethnicity

San Francisco

Source: ClinicalTrials.gov · NCT02431507 · last updated 2026-01-22